source
- AstraZeneca teams with insitro in up to $1.5 billion AI partnership to target MASH and cardiomyopathiesAstraZeneca announced a partnership with AI-driven biotech insitro, committing up to $1.5 billion to discover new drug targets for metabolic dysfunction-associated steatohepatitis (MASH) and cardio…
- FDA launches Rare Disease Framework Initiative to overhaul review processThe FDA announced a new Rare Disease Framework Initiative aimed at redesigning how therapies for rare conditions are regulated. The initiative will move away from a one-size-fits-all model, instea…